PPCB (Propanc Biopharma) Ending Cash Position: $0.44 Mil (As of Mar. 2026)


PPCB Propanc Biopharma Inc PPCB
29 GF Score
Price $1.79
! 2 Warning Signs
View Full Analysis

What is Propanc Biopharma Ending Cash Position?

Propanc Biopharma PPCB +22.92% 29 Ending Cash Position is $0.44 Mil as of Mar. 2026. GuruFocus rates PPCB with a GF Score™ of 29/100. The stock has 2 warning signs investors should review.

Propanc Biopharma's Ending Cash Position for the quarter that ended in Mar. 2026 was $0.44 Mil.

Propanc Biopharma's quarterly Ending Cash Position declined from Sep. 2025 ($0.60 Mil) to Dec. 2025 ($0.56 Mil) and declined from Dec. 2025 ($0.56 Mil) to Mar. 2026 ($0.44 Mil).

Propanc Biopharma's annual Ending Cash Position increased from Jun. 2023 ($0.01 Mil) to Jun. 2024 ($0.02 Mil) but then declined from Jun. 2024 ($0.02 Mil) to Jun. 2025 ($0.01 Mil).

Propanc Biopharma Ending Cash Position Related Terms

Propanc Biopharma Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Propanc Biopharma's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Propanc Biopharma Ending Cash Position Chart

Propanc Biopharma Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.01 0.02 0.01

Propanc Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.01 0.60 0.56 0.44
PPCB
29GF Score
Propanc Biopharma Inc PPCB
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Propanc Biopharma Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Propanc Biopharma's Ending Cash Position for the fiscal year that ended in Jun. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=0.021+-0.009
=0.01

Propanc Biopharma's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0.561+-0.117
=0.44

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $0.44 Mil mean?
Propanc Biopharma (PPCB) has a Ending Cash Position of $0.44 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Propanc Biopharma and its competitors.
Is Propanc Biopharma's Ending Cash Position too high?
Propanc Biopharma's current Ending Cash Position is $0.44 Mil. Overall, Propanc Biopharma has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Propanc Biopharma's Ending Cash Position compare to GRI and BGMS?
Propanc Biopharma's Ending Cash Position of $0.44 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Propanc Biopharma and its competitors. Propanc Biopharma's current Ending Cash Position is $0.44 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Propanc Biopharma stock overvalued right now?
Propanc Biopharma (PPCB) has a current Ending Cash Position of $0.44 Mil. The current Ending Cash Position is $0.44 Mil. Propanc Biopharma's overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Propanc Biopharma (PPCB), the current Ending Cash Position is $0.44 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Propanc Biopharma Business Description

Address 302, 6 Butler Street, Cambwerwell, VIC, AUS, 3124
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.
29GF Score

Get the complete analysis for PPCB

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.79
Price